Classiq, a quantum computing software company, and Quantum Intelligence Corp. (QIC, Korea) have partnered to accelerate drug development using quantum computing. The collaboration will use the Classiq platform to explore quantum computing applications in pharmacology, including drug discovery, prediction of side effects, and drug interactions. The goal is to enhance the efficiency and accuracy of drug development by integrating Classiq’s quantum computing platform with QIC’s drug development platform. QIC’s CEO, Hwan ho Choi, and Classiq’s CEO, Nir Minerbi, both emphasized the potential of this partnership to revolutionize drug development.
Quantum Computing and Drug Development: A New Partnership
Classiq, a quantum computing software company, and Quantum Intelligence Corp. (QIC, Korea) have announced a joint research initiative aimed at accelerating drug development by applying quantum computing to pharmacology. This collaboration is part of Classiq’s Quantum Computing For Life Sciences & Healthcare Center, which was launched in partnership with NVIDIA last year.
The primary objective of this partnership is to leverage the Classiq platform to investigate the potential of quantum computing in pharmacology. This includes the discovery and design of new drug candidates, as well as the prediction of potential side effects and interactions. The collaboration aims to enhance the efficiency and accuracy of drug development by integrating Classiq’s quantum computing platform with QIC’s drug development platform.
QIC, a South Korean startup, is developing the QUEST-ADMET platform based on quantum computing and AI technologies. The platform is designed to predict compound properties through electronic charge distribution algorithms, which can efficiently assess the efficacy and safety of drug candidates.
Classiq’s Role in the Partnership
Classiq provides a quantum development platform that simplifies and accelerates the development of complex quantum software and applications. The platform’s built-in functions, GitHub repository, and seamless execution on quantum computing hardware will be key components in the research to develop pharmacology applications.
Classiq’s core technology, algorithmic quantum circuit compilation, is designed to power the quantum ecosystem of today and the future. The company works closely with quantum cloud providers and advanced computation hardware developers, providing software for use with quantum computers, high-performance computing (HPC), and quantum simulators.
Quantum Intelligence Corp.’s Contribution
Quantum Intelligence Corp. (QIC) is a company based in Seoul, South Korea, that is integrating quantum computing with artificial intelligence to revolutionize drug discovery. Using its advanced QUEST-ADMET platform and the Quantum-Dock module, QIC aims to outperform conventional drug development approaches in both accuracy and speed, offering highly precise predictions of drug efficacy and safety.
QIC’s global expansion is supported by strategic partnerships, including collaborations with Oxford Quantum Circuits (UK), Quandela (France), and QuEra Computing (US), alongside a joint venture with 48Hour Discovery (Canada). These partnerships enhance QIC’s presence in key North American, European, and Asian markets.
The Future of Drug Development
This partnership marks a significant step towards a new era of accelerated drug development using quantum computing technology. By combining Classiq’s quantum computing technology with QIC’s drug development platform, the collaboration aims to achieve significant improvements in the efficiency and accuracy of drug development.
The company’s strategy to license out drug candidates developed with its quantum computing technology marks a paradigm shift in the pharmaceutical industry, underscoring Quantum Intelligence’s potential for significant growth.
About Classiq and Quantum Intelligence Corp.
Classiq Technologies provides an all-encompassing platform (IDE, compiler, and OS) with a single point of entry into quantum computing, taking users from algorithm design to execution. The high-level descriptive quantum software development environment, tailored to all levels of developer proficiency, automates quantum programming.
Founded in 2020 by CEO Dr. Choi Hwanho and CTO Dr. Kang Hong-seok, Quantum Intelligence Corp. (QIC) is at the forefront of integrating quantum computing with artificial intelligence to revolutionize drug discovery. QIC’s diverse team of experts in quantum physics, molecular modeling, and AI is committed to driving innovations that optimize the drug development process.
External Link: Click Here For More
